Most Recent
Sandoz ordered to pay Lundbeck over $26.3M for infringing Lexapro patent
Intellectual Property 2019-02-19 10:18 pm By Christine Caulfield

Generic drug maker Sandoz must pay $26.34 million to Danish pharmacuetical giant Lundbeck and a subsidiary for infringing the Australian patent behind the blockbuster antidepressant Lexapro, a judge has found.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Neurim wins fight to amend patent for top-selling Circadin amid infringement case
Intellectual Property 2019-02-19 7:35 pm By Christine Caulfield

Drug maker Neurim Pharmaceuticals has won a bid to amend its Australian patent for top selling sleeping pill Circadin over the protests of two generic pharmaceutical companies, whch argued Neurim had purposely delayed the application to gain an unfair advantage in its infringement suit.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Allergan snips Botox trade mark case against Self Care
Intellectual Property 2019-02-18 9:17 pm By Miklos Bolza

Pharmaceutical giant Allergan has streamlined its trade mark case against Self Care Corporation, which makes products marketed as Botox alternatives.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Apotex, Cipla resolve claims over Dymista patent
Intellectual Property 2019-02-18 1:34 pm By Cat Fredenburgh

Canadian generic manufacturer Apotex has agreed to drop its lawsuit against India’s Cipla seeking to invalidate its Australian patent for popular nasal spray Dymista.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Slater & Gordon mulls class action over doctors’ ‘excessive’ work hours
Class Actions 2019-02-15 11:45 pm By Cat Fredenburgh

Law firm Slater and Gordon is investigating a class action against hospitals for encouraging “excessive and unsafe” work hours by doctors, some of whom the firm found routinely work up to 100 hours per week.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Who reads law firm websites? Judge skeptical of online class action notice
Class Actions 2019-02-14 9:04 pm By Miklos Bolza

A judge overseeing a class action against the NSW government over a contractor who sold injured workers’ information to Bannister Law has questioned the effectiveness of placing ads for group members on law firm websites, saying she didn’t think it would “draw the matter to anyone’s attention”.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Mylan appeals loss to Sun Pharma over cholesterol drug patent
Intellectual Property 2019-02-14 11:31 am By Cat Fredenburgh

Mylan has appealed a ruling invaliding claims of its cholesterol drug patent and dismissing its patent infringement case against Sun Pharma.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

TPI agrees to stop selling high codeine poppy seed, for now
Intellectual Property 2019-02-12 9:37 pm By Cat Fredenburgh

Poppy processor TPI Enterprises has agreed to stop selling seed from high codeine poppy plants while it defends a lawsuit by rival Tasmanian Alkaloids alleging TPI infringed two of its innovation patents for high codeine-concentrated poppy.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Cryosite offers $1M to resolve ACCC’s first ‘gun-jumping’ case
Competition & Consumer Protection 2019-02-11 9:31 pm By Christine Caulfield

Biotech company Cryosite has agreed to pay $1.05 million to settle the competition regulator’s landmark case alleging it jumped the gun on a proposed merger agreement with rival Cell Care.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

AFT not ready to take its medicine for ‘misleading’ Maxigesic ads
Appeals 2019-02-08 10:54 pm By Cat Fredenburgh

AFT Pharmaceuticals has launched a partial challenge to a court ruling that its Maxigesic ads made a number of misleading claims, including that the drug provides stronger and more effective relief than Reckitt Benckiser’s Nuromol.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?